Welcome to the e-CCO Library Archive!

Filter:

P311

No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results

Authors:

K. Malickova1, D. Duricova*2, M. Kolar2, M. Bortlik2, V. Hruba2, N. Machkova2, K. Mitrova2, M. Lukas Jr.2, M. Lukas2

1First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 2ISCARE, IBD clinical and research centre, Prague, Czech Republic

P312

Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO members

Authors:

S. Danese*1, 2, G. Fiorino1, P. Michetti3

1Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, 2Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy, 3Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland

P313

Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitis

Authors:

M. Choy*1, 2, 3, D. Seah1, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W. R. Connell2, G. Moore7, D. Van Langenberg8, P. De Cruz1, 3

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, 3University of Melbourne, Department of Medicine, Melbourne, Australia, 4Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, 5Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 6The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 7Monash Health, Department of Gastroenterology, Melbourne, Australia, 8Eastern Health, Department of Gastroenterology, Melbourne, Australia

P314

Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum level

Authors:

U. Helwig*1, F. Lutter1, N. Koppka2, S. Schreiber3

1University of Kiel, Medical Practice for Internal Medicine, Oldenburg, Germany, 2Medical Practice for Internal Medicine, Oldenburg, Germany, 3Department of Internal Medicine I - Gastroenterology, Hepatology, Nutrition and Geriatric Medicine, University Hospital Schleswig-Holstein, campus Kiel, Kiel, Germany

P315

Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study

Authors:

P. Michetti*1, L. Peyrin-Biroulet2, M. S. Silverberg3, E. Louis4, J. Weinman5, J. Sommer6, J. Petersson7, B. Pappalardo7, P. Nurwakagari8

1IBD Centre La Source-Beaulieu, Lausanne, Switzerland, 2Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandoeuvre-les-Nancy, France, 3Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 4CHU de Liège et Université de Liège, Liège, Belgium, 5Institute of Pharmaceutical Sciences & Institute of Psychiatry, King’s College, London, United Kingdom, 6GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, 7AbbVie Inc., North Chicago, Illinois, United States, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

P316

Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeks

Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain

P317

Health care costs associated with standard inflammatory bowel disease care in Australia and opportunities to improve care: a tertiary centre study

Authors:

B. Jackson*1, R. Ma1, A. Gorelik2, D. Con1, D. Liew2, P. De Cruz1

1Austin Health, Gastroenterology, Melbourne, Australia, 2Melbourne Health, Melbourne, Australia

P318

Does anti-tumour necrosis factor therapy decrease the risk of initial intestinal resection after the diagnosis of Crohn’s disease? A retrospective single-centre study

Authors:

Y. Nagata*1, M. Esaki1, A. Hirano1, J. Umeno1, Y. Maehata1, T. Torisu1, T. Moriyama1, T. Matsumoto2, T. Kitazono1

1Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 2School of Medicine, Iwate Medical University, Division of Gastroenterology, Department of Internal Medicine, Morioka, Japan

P319

Combining anti-inflammatory treatment with antiviral treatment in severe cytomegalovirus-positive ulcerative colitis does not affect colectomy rate: a retrospective European multicentre study

Authors:

U. Kopylov*1, K. Papamichael2, 3, K. Katsanos4, M. Waterman5, A. Bar-Gil Shitrit6, T. Boysen7, F. Portela8, A. Peixoto9, A. Szilagyi10, M. Silva9, G. Maconi11, O. Har-Noy1, P. Bossuyt12, G. Mantzaris2, M. Barreiro de Acosta13, M. Chaparro14, D. Christodoulou4, R. Eliakim1, J.-F. Rahier15, F. Magro9, S. Ben-Horin16, X. Roblin17

1Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, 2Evaggelismos Hospital, Gastroenterology, Athens, Greece, 3KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 4University of Ioannina, Gastroenterology, Ioannina, Greece, 5Rambam Healthcare Campus, Gastroenterology, Haifa, Israel, 6Shaare Zedek Medical Centre, Digestive diseases Institute, Jerusalem, Israel, 7Herlev University Hospital, Gastroenterology, Herlev, Denmark, 8Hospital Universidade Coimbra, Gastroenterology, Coimbra, Portugal, 9Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 10Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, 11Luigi Sacco’ University Hospital, Gastroenterology, Milan, Italy, 12Imelda GI clinical research Centre,, Gastroenterology, Bonheiden, Belgium, 13University Hospital of Santiago de Compostela, IBD Unit, Gastroenterology Department, Santiago de Compostela, Spain, 14Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 15CHU Dinant Godinne, UCL Namur, Gastroenterology, Yvoir, Belgium, 16Chaim Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel, 17CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France

P320

Clinical and economic effect of short infliximab infusion protocol in patients with inflammatory bowel diseases: a multicentre study

Authors:

M. Cappello*1, G. Costantino2, A.C. Privitera3, F. Bossa4, A. Lauria5, L. Grossi6, M. B. Principi7, N. Della Valle8, M. A. Veneziano9, D. Crocchiolo9

1University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, 2Università di Messina, Dipartimento di Medicina Interna e Terapia Medica, Messina, Italy, 3Azienda Ospedaliera per l’Emergenza, Ospedale Cannizzaro, Catania, Gastroenterologia, Catania, Italy, 4Casa Sollievo della Sofferenza, Gastroenterologia, S. Giovanni Rotondo, Foggia, Italy, 5A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Gastroenterologia e Endoscopia Digestiva, Reggio Calabria, Italy, 6Ospedale Spirito Santo, Pescara, Fisiopatologia Digestiva, Pescara, Italy, 7Policlinico, Department of Gastroenterology, Bari, Italy, 8Ospedale di Foggia, Gastroenterologia, Foggia, Italy, 9MSD Italy, Rome, Italy

P321

Mucosal healing in a cohort of inflammatory bowel diseases paediatric patients in clinical remission

Authors:

F. P. Giugliano1, C. Strisciuglio*2, M. Martinelli1, M. Andreozzi1, S. Cenni1, A. Staiano1, E. Miele1

1University Federico II, Department of Translational Medical Science, Section of Paediatrics, Naples, Italy, 2Second University of Naples, Department of Woman, Child and General and Specialised Surgery, Naples, Italy

P322

Complications to parenteral therapy in patients with intestinal failure because of inflammatory bowel disease: A retrospective cohort study

Authors:

R. Lorentsen, L. K. Munck, S. Wildt*

Køge University Hospital, and Faculty of Health Sciences, University of Copenhagen, Section of Gastroenterology, Medical Department, Køge, Denmark

P323

Prevalence of vitamin D deficiency in patients with inflammatory bowel disease

Authors:

N. Toke*, P. Kakkadasam Ramaswamy, B. Sebastian, S. Mathai, C. Panackel

Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India

P324

Comparative short and long-term efficacy of infliximab and adalimumab in patients with ulcerative colitis refractory to corticosteroids: a retrospective study

Authors:

N. Yoshimura*, M. Sako, M. Takazoe

Tokyo Yamate Medical Centre, Department of Internal Medicine, Tokyo, Japan

P325

Efficacy, safety, and long-term outcome of endoscopic dilation therapy for stricturing Crohn’s disease of the upper gastrointestinal tract: a combined analysis of 127 endoscopic balloon dilation procedures

Authors:

D. Bettenworth*1, M. M. Mücke1, A. Singh2, R. Lopez3, F. Rieder4, 5

1University Hospital Münster, Department of Medicine B, Münster, Germany, 2Cleveland Clinic Foundation, Department of Hospital Medicine, Cleveland, Ohio, United States, 3Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Cleveland, Ohio, United States, 4Cleveland Clinic Foundation, Department of Gastroenterology, Hepatology & Nutrition, Digestive Disease Institute, Cleveland, Ohio, United States, 5Cleveland Clinic Foundation, Department of Pathobiology, Cleveland, Ohio, United States

P326

Validation of CUCQ-8 Questionnaire for Quality of Life Assessment in IBD Patients

Authors:

C. McGinley*1, C. Mowat2, M. Groome2, J. Todd2, N. Reynolds2

1University of Dundee, Dundee, United Kingdom, 2Ninewells Hospital and Medical School, Department of Gastroenterology, Dundee, United Kingdom

P327

Biosimilar infliximab in real-life Crohn’s disease’s anti-TNFalfa naïve patients: a comparative observational cohort study (SIMRECRO study)

Authors:

L. Carvalho Lourenço*, V. Anapaz, A. M. Oliveira, J. Branco, M. Cardoso, C. Graça Rodrigues, L. Santos, D. Horta, A. Martins, J. Reis

Hospital Prof Dr Fernando Fonseca, Serviço de Gastrenterologia, Amadora, Portugal

P328

Factors related to short- and long-term treatment results and usefulness of infliximab for refractory ulcerative colitis

Authors:

Y. Takada*, S. Yasukawa, R. Amano, M. Yasaka, N. Takatsu, Y. Yano, F. Hirai

Fukukuoka University Chikushi hospital, Chikushino-shi, Japan

P329

Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study

Authors:

S. Hamanaka*, T. Nakagawa, H. Koseki, T. Sakurai, T. Taida, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura, T. Katsuno, M. Arai, O. Yokosuka

Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba City, Japan

P330

Vitamin D insufficiency in patients with inflammatory bowel disease

Authors:

M. d. C. Martos Plasencia*, C. Verdejo Gil, R. H. Lorente Poyatos, E. De la Santa Belda, M. Peña Gómez, R. Salmoral Luque, B. López Viedma, J. Olmedo Camacho

University Hospital of Ciudad Real, Gastroenterology and Hepatology Department, Ciudad Real, Spain